Oxra-L Tablet
Generic: Dapagliflozin/Linagliptinby Sun Pharmaceutical Industries Ltd

Select pack size
Similar medicines
View allAbout Oxra-L Tablet
Oxra-L 10 is a Sun Pharma tablet that puts two type 2 diabetes medicines into one: dapagliflozin 10 mg, an SGLT2 inhibitor that makes the kidneys pass more glucose into the urine, and linagliptin 5 mg, a DPP-4 inhibitor that raises insulin release and lowers glucagon when blood glucose is high (Farxiga US label 12.1; Tradjenta US label 12.2). Tata 1mg, PharmEasy and Apollo Pharmacy all list it as dapagliflozin 10 mg plus linagliptin 5 mg in strips of 10 tablets, marketed by Sun Pharmaceutical Industries Ltd. It is taken as one tablet once a day. We sell it in packs of 60, 120 and 240 tablets, from $0.68 a tablet in the 240 pack.
Read this before you order. India's drug regulator (CDSCO) approved this combination in July 2023 for type 2 diabetes not controlled on metformin. We found no approval of a dapagliflozin and linagliptin combination tablet by the FDA, MHRA, TGA or Health Canada; in those countries the two medicines are licensed as separate tablets (Farxiga or Forxiga, and Tradjenta or Trajenta). No trial has tested Oxra-L itself for heart or kidney outcomes. It is a prescription medicine that needs a doctor: a kidney and fluid check before you start, a plan for sick days and surgery, and a review of any insulin or sulfonylurea. The warnings that matter most are ketoacidosis and serious genital infections (from dapagliflozin) and pancreatitis (from linagliptin).
Oxra-L 10 at a glance
| Active ingredients | Dapagliflozin 10 mg and linagliptin 5 mg per tablet (Tata 1mg, PharmEasy, Apollo). Our product photo shows the carton front: "Dapagliflozin and Linagliptin Tablets, OXRA-L 10" |
| Brand and maker | Oxra-L 10, Sun Pharmaceutical Industries Ltd (marketer on Tata 1mg and Apollo). PharmEasy gives a manufacturing address at Exemed Pharmaceuticals, Vapi, Gujarat; country of origin India |
| Regulatory status | Combination approved in India (CDSCO, 3 July 2023). Not approved as a combination by the FDA, MHRA, TGA or Health Canada (we found none on Drugs@FDA, the UK emc, healthdirect for Australia, or the Health Canada database). Each ingredient is licensed on its own in all four countries |
| Usual dose | One tablet once daily. Linagliptin: 5 mg once daily is the labelled dose (US 2.1; UK 4.2). Dapagliflozin: 10 mg is the top US dose for glucose control; the US label starts glucose control at 5 mg (US 2.2) |
| Half-life | Dapagliflozin about 12.9 hours after a 10 mg dose (Farxiga 12.3). Linagliptin: effective half-life for accumulation about 12 hours; terminal half-life over 100 hours because it binds tightly to DPP-4 (Tradjenta 12.3) |
| Packs | 60, 120 and 240 tablets (Indian strips of 10) |
| Price per tablet | $0.88 (60 pack), $0.78 (120 pack), $0.68 (240 pack), before shipping |
| Delivery | 7 to 14 business days to the US, UK, Australia and Canada; $25 shipping under $149, free from $149 |
What the approval covers, and what it does not
India. CDSCO's list of fixed dose combinations approved in 2023 records "Linagliptin 5mg + Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Film Coated Tablets" for use "In patients with type 2 Diabetes Mellitus inadequately controlled on Metformin", approved 3 July 2023. In plain words, the Indian approval is for adults already taking metformin whose glucose is still too high, so in most cases Oxra-L 10 is meant to be taken alongside metformin, not instead of it. CDSCO added a dapagliflozin 5 mg plus linagliptin 5 mg strength on 11 January 2024. We have not seen Sun Pharma's own prescribing information for Oxra-L.
US, UK, Australia and Canada. We searched Drugs@FDA (through openFDA), the UK emc medicines database, the EMA medicines list, healthdirect (which draws on the Australian register) and the Health Canada Drug Product Database, and found no product combining dapagliflozin with linagliptin. The licensed combinations of these two drug classes are different pairs: empagliflozin with linagliptin (Glyxambi; FDA, EMA and on the UK emc) and dapagliflozin with saxagliptin (Qtern; EMA, and FDA, where Drugs@FDA now lists Qtern as discontinued, though generic dapagliflozin and saxagliptin tablets are still listed). Dapagliflozin and linagliptin are each licensed separately in all four countries.
What that means for you. The two ingredients are well studied on their own, and their labels are the best guide to dose and safety, so this page uses the current US Farxiga and Tradjenta labels and the UK product information for each medicine. None of those labels covers this combination tablet, and no regulator in the US, UK, Australia or Canada has reviewed it.
Price per tablet
Prices below are as of November 2026; the pack selector shows the current price.
| Pack | Price | Per tablet | Shipping | Per tablet with shipping | Lasts at 1 a day |
|---|---|---|---|---|---|
| 60 tablets | $53 | $0.88 | $25 | $1.30 | 60 days |
| 120 tablets | $94 | $0.78 | $25 | $0.99 | 120 days |
| 240 tablets | $164 | $0.68 | Free | $0.68 | 240 days |
The 60 and 120 packs are under the $149 free shipping line, so each carries $25 shipping; the 240 pack ships free. The bigger packs are also cheaper per tablet before shipping. The 240 pack covers about eight months (our arithmetic), so agree the plan with your doctor first and check that the expiry date on the strips runs past the date you will finish them.
Compared with Farxiga, Tradjenta and US generics
| Option | What it is | Cost per day | Source of the price |
|---|---|---|---|
| Oxra-L 10 (ours) | Dapagliflozin 10 mg + linagliptin 5 mg in one tablet; Indian pack | $0.68 to $0.88 before shipping | Our prices, November 2026 |
| US generic dapagliflozin 10 mg alone | FDA approved generic | $0.18565 | NADAC, 21 NDC rows |
| US Farxiga 10 mg alone | FDA approved brand | $12.07441 | NADAC, 3 NDC rows |
| US Tradjenta 5 mg alone | FDA approved brand | $16.79294 | NADAC, 3 NDC rows |
| US generic dapagliflozin + Tradjenta | The same two medicines as separate tablets | $16.98 | Sum of the NADAC rows (our arithmetic) |
| US Glyxambi 10 mg/5 mg | Empagliflozin + linagliptin, a different licensed pair | $11.23860 | NADAC, 3 NDC rows |
| Our Forxiga 10mg + Trajenta 5mg | Both brands as separate tablets from us | About $3.87 before shipping | Forxiga 84 pack $2.54 + Trajenta 60 pack $1.33 per tablet |
NADAC is the average price US pharmacies pay to buy a medicine, published by Medicaid; it is not what a patient pays at the counter. All rows above are from the NADAC file as of 18 November 2026, effective 18 November 2026. There were no generic linagliptin rows in that file, so we have no US pharmacy price for generic linagliptin even though Drugs@FDA lists approved generic applications. For Medicare Part D, CMS has agreed a negotiated price of $78 for a 30-day supply of Tradjenta from 1 January 2027, against a 2024 list price of $488; what a patient pays depends on the plan.
The plain comparison. If your doctor wants you on dapagliflozin alone, US generic dapagliflozin at about 19 cents a tablet is far cheaper than Oxra-L 10, which costs about 3.7 to 4.8 times as much before shipping (our arithmetic). If you need both medicines, the US cost of generic dapagliflozin plus brand Tradjenta is much higher than ours, because there is no generic linagliptin in NADAC yet. The trade off is that Oxra-L 10 is an Indian combination no US, UK, Australian or Canadian regulator has reviewed, while the separate tablets are licensed products. If you are in the US with a prescription and insurance, ask your pharmacist what the two separate medicines would cost you before ordering from us.
Other combinations we list. Vysov D pairs vildagliptin 100 mg with dapagliflozin 5 mg. It is a different product with a different DPP-4 inhibitor and half the dapagliflozin; do not swap one for the other without your doctor.
Do you need both medicines?
That is a decision for your doctor, but here is what the evidence we could check says.
- Adding dapagliflozin to a DPP-4 inhibitor. In a 24 week US label trial, dapagliflozin 10 mg added to sitagliptin (another DPP-4 inhibitor), with or without metformin, lowered HbA1c by 0.48 points more than placebo, and 35.4% against 16.6% had an HbA1c fall of at least 0.7 points (Farxiga US label, Table 12). The label trials used sitagliptin, not linagliptin.
- Trials of this pair. A 16 week Indian trial (PMID 37957465) gave 232 adults on metformin either a dapagliflozin 10 mg plus linagliptin 5 mg combination tablet or linagliptin 5 mg. HbA1c fell by 1.28 points on the combination against 0.83 on linagliptin alone. The trial was funded by Alkem Laboratories and six authors work in Alkem's medical department; the paper does not name the maker of the tablet studied, and it was not a trial of Sun's Oxra-L.
- Heart and kidney outcomes. The heart failure and kidney results in the Farxiga label come from trials of Farxiga, and the CARMELINA and CAROLINA safety results come from trials of Tradjenta. No outcome trial has tested Oxra-L 10.
- Our view. A combination tablet makes most sense for someone whose doctor has already settled on dapagliflozin 10 mg and linagliptin 5 mg together and wants fewer tablets. It is not a first diabetes medicine, and it does not replace metformin where metformin is prescribed.
Which strength to choose
| Option | Dapagliflozin | Linagliptin | How it fits the labels |
|---|---|---|---|
| Oxra-L 10 (this product) | 10 mg | 5 mg | Dapagliflozin 10 mg is the US dose after 5 mg if more glucose control is needed (2.2), and the maximum: the US label calls 150 mg 15 times "the recommended maximum dose" (12.2). Linagliptin 5 mg once daily is the only labelled dose (US 2.1; UK 4.2) |
| Oxra-L 5 (we do not sell it) | 5 mg | 5 mg | Indian listings show an Oxra-L 5; CDSCO approved a 5 mg plus 5 mg strength in January 2024. We have not checked its pack. Dapagliflozin 5 mg is the US starting dose for glucose control (2.2) |
| Separate tablets | Forxiga 5mg or Forxiga 10mg | Trajenta 5mg | Lets your doctor change the dapagliflozin dose or stop one medicine without stopping the other |
| More than one Oxra-L 10 a day | 20 mg or more | 10 mg or more | Above both labelled doses. Do not do this |
Because the US label starts glucose control at dapagliflozin 5 mg, a doctor following it would not usually begin with Oxra-L 10 unless you already take dapagliflozin 10 mg. Moving between strengths is your doctor's decision.
How to take Oxra-L 10
- One tablet once a day, with or without food (both US labels say either is fine: Farxiga 12.3, Tradjenta 2.1).
- Before you start, your doctor should check kidney function and fluid status, and correct any fluid loss first (Farxiga 2.1).
- Missed dose: take it as soon as you remember, but do not double up the next dose (Farxiga 2.5). The Tradjenta Medication Guide adds that if you only remember when the next dose is due, skip the missed one.
- Keep taking metformin or any other diabetes medicine your doctor has prescribed, unless they tell you otherwise.
- Surgery: the Farxiga label says withhold dapagliflozin "for at least 3 days, if possible" before surgery or procedures with prolonged fasting, and restart when you are stable and eating and drinking (2.4). With a combination tablet, holding it stops your linagliptin too (our note), so ask how your glucose will be covered.
- Sick days: if you cannot eat or drink as usual, or lose fluid through vomiting, diarrhoea or being in the sun too long, call your doctor right away (Farxiga Medication Guide).
- Expect a positive urine glucose test. Urine glucose and 1,5-AG tests are not reliable for checking control while you take an SGLT2 inhibitor (Farxiga 7).
Kidneys, liver and other groups needing care
- Kidney function. The Farxiga label says dapagliflozin "is not recommended for use to improve glycemic control" in type 2 diabetes with an eGFR below 45 mL/min/1.73 m2, where it "is likely to be ineffective" (1, 2.2). Linagliptin needs no dose change for kidney function (Tradjenta 8.6; UK 4.2). So if your eGFR falls below 45, the glucose lowering from the dapagliflozin half of Oxra-L 10 is not expected to work, and your doctor may need to rethink the combination (our reading of the two labels).
- Fluid loss and low blood pressure. People with an eGFR below 60, older people and people on loop diuretics "may be at increased risk for volume depletion or hypotension"; check volume status and kidney function before starting (Farxiga 5.2). In people 65 and over, a higher proportion on Farxiga had hypotension (Farxiga 8.5).
- Insulin or a sulfonylurea. Both labels say a lower dose of insulin or the sulfonylurea may be needed to reduce the risk of low blood sugar (Farxiga 5.4; Tradjenta 5.2). In the Tradjenta trial added to metformin and a sulfonylurea, glucose below 54 mg/dL occurred in 8.1% against 5.3% on placebo (Tradjenta Table 2).
- Severe kidney impairment with insulin. "The use of TRADJENTA in combination with insulin in subjects with severe renal impairment was associated with a higher rate of hypoglycemia" (Tradjenta 5.2).
- Heart failure risk. The Tradjenta label notes heart failure was linked to "two other members of the DPP-4 inhibitor class" in outcome trials, and asks doctors to weigh the risks in people at risk of heart failure, such as those with prior heart failure or kidney impairment (5.6).
- Liver. Neither US label asks for a dose change; for dapagliflozin in severe liver impairment the benefit and risk "should be individually assessed" (Farxiga 8.7; Tradjenta 8.7). The UK linagliptin label says clinical experience in liver impairment "is lacking" (4.2).
- Medicines that interact. Lithium levels may fall with an SGLT2 inhibitor, so they should be checked more often (Farxiga 7). With a strong P-gp or CYP3A4 inducer such as rifampin, "use of alternative treatments is strongly recommended" because linagliptin may work less well (Tradjenta 7.1).
- Children. Linagliptin's effectiveness "was not demonstrated" in a trial of 157 children aged 10 to 17 (Tradjenta 8.4), and the UK label says "treatment of children and adolescents with linagliptin is not recommended" (4.2). Oxra-L 10 is for adults.
Ketoacidosis and other dapagliflozin warnings
Ketoacidosis. "There have been postmarketing reports of fatal events of ketoacidosis in patients with type 2 diabetes mellitus using SGLT2 inhibitors, including FARXIGA" (Farxiga 5.1). Type 2 diabetes and pancreatic disorders such as past pancreatitis or pancreatic surgery are risk factors. Triggers listed in the label include missed or reduced insulin, fever, eating less, a ketogenic diet, surgery, fluid loss and alcohol abuse. It can happen with near normal glucose: "Blood glucose levels at presentation may be below those typically expected for diabetic ketoacidosis (e.g., less than 250 mg/dL)." The label tells patients to stop and seek medical attention immediately if symptoms occur.
Genital and urinary infections. Dapagliflozin increases the risk of urinary tract and genital fungal infections in men and women. Serious infections, including urosepsis, pyelonephritis and Fournier's gangrene ("a rare life-threatening infection requiring urgent surgical intervention"), have occurred with SGLT2 inhibitors including Farxiga; "In patients with Fournier's gangrene, serious outcomes have included multiple surgeries and death" (Farxiga 5.3).
Fluid loss and kidney injury. There have been post-marketing reports of acute kidney injury, "some requiring hospitalization and dialysis", in people with type 2 diabetes on SGLT2 inhibitors including Farxiga (5.2).
Foot care. The UK Forxiga label notes more lower limb amputations, mainly of the toe, in long term SGLT2 inhibitor studies, says it is unknown whether this is a class effect, and says routine preventative foot care counselling is important (4.4).
Pancreatitis and other linagliptin warnings
Pancreatitis. "Acute pancreatitis, including fatal pancreatitis, has been reported in patients treated with TRADJENTA." In CARMELINA it occurred in 0.3% on Tradjenta against 0.1% on placebo, and two patients on Tradjenta died of it (Tradjenta 5.1). If pancreatitis is suspected, the drug should be stopped promptly. The UK label adds that if it is confirmed, linagliptin "should not be restarted" (4.4).
Bullous pemphigoid. A blistering skin disease, reported in 0.2% on Tradjenta and no one on placebo in CARMELINA, three of whom were admitted to hospital. Report blisters or skin erosions; if bullous pemphigoid is suspected the drug should be stopped and a dermatologist referral considered (Tradjenta 5.5).
Severe joint pain. Post-marketing reports of "severe and disabling arthralgia", starting anywhere from one day to years after starting; symptoms eased on stopping (Tradjenta 5.4).
Allergic reactions. Anaphylaxis, angioedema and exfoliative skin conditions have been reported, mostly within the first 3 months, some after the first dose (Tradjenta 5.3). Serious hypersensitivity reactions, including anaphylaxis and angioedema, have also been reported with Farxiga (Farxiga 4).
Side effects
There is no side effect table for this combination tablet in any label we could check. These are the label tables for each ingredient on its own, from separate trials; they are not head to head and do not add together.
| Dapagliflozin 10 mg (Farxiga US Table 1, 12 trials) | Farxiga 10 mg | Placebo |
|---|---|---|
| Genital fungal infections, women | 6.9% | 1.5% |
| Nasopharyngitis | 6.3% | 6.2% |
| Urinary tract infections | 4.3% | 3.7% |
| Back pain | 4.2% | 3.2% |
| Increased urination | 3.8% | 1.7% |
| Genital fungal infections, men | 2.7% | 0.3% |
| Nausea | 2.5% | 2.4% |
| Dyslipidemia | 2.5% | 1.5% |
| Influenza | 2.3% | 2.3% |
| Discomfort with urination | 2.1% | 0.7% |
| Constipation | 1.9% | 1.5% |
| Pain in extremity | 1.7% | 1.4% |
| Linagliptin 5 mg (Tradjenta US Table 1, 14 trials) | Tradjenta 5 mg | Placebo |
|---|---|---|
| Nasopharyngitis | 7.0% | 6.1% |
| Diarrhea | 3.3% | 3.0% |
| Cough | 2.1% | 1.4% |
The Farxiga table shows the 10 mg and placebo columns of the label table (the label also has a 5 mg column). Linagliptin also raised lipase in one trial: levels above 3 times the upper limit of normal in 8.2% against 1.7% on placebo; the label says the meaning of this is unknown without pancreatitis symptoms (Tradjenta 6.1).
When to get urgent help
- Signs of ketoacidosis, even if your glucose reading is not very high: nausea, vomiting, stomach area pain, tiredness or trouble breathing (Farxiga Medication Guide).
- Pain or tenderness, swelling or redness in the genital area or the area between the genitals and anus, with fever or feeling very unwell (Fournier's gangrene; Farxiga 5.3).
- Stomach pain that is severe and will not go away, which may spread to your back, with or without vomiting (pancreatitis; Tradjenta Medication Guide).
- Swelling of the face, lips, tongue or throat, difficulty breathing or swallowing, hives, or a rash with flaking or peeling skin (Farxiga and Tradjenta Medication Guides).
- Blisters or breakdown of the outer layer of skin (bullous pemphigoid; tell your doctor right away).
- Feeling faint, dizzy or very weak when you stand, or passing much less urine (fluid loss or kidney injury).
- Increasing shortness of breath, rapid weight gain or swelling of the feet (heart failure; Tradjenta 17).
- Low blood sugar that does not settle, especially if you also take insulin or a sulfonylurea.
- More than one tablet taken: both US labels suggest contacting a poison centre (US Poison Help line 1-800-222-1222) or a medical toxicologist (Farxiga 10; Tradjenta 10).
Tell emergency staff that you take dapagliflozin and linagliptin, how much and when you last took it.
Who should not take Oxra-L 10
Never take it if you are allergic to linagliptin, have had a serious allergic reaction to dapagliflozin, or are allergic to any ingredient of the tablet. The Farxiga US label contraindicates it after "a serious hypersensitivity reaction" (4); the Tradjenta US label (4) and the UK linagliptin label (4.3) contraindicate it with any hypersensitivity to linagliptin.
The labels advise against it, or say it should not be used, in these cases:
- Type 1 diabetes: Farxiga "is not recommended for use to improve glycemic control" in type 1 diabetes (US 1) and raises the risk of ketoacidosis there (5.1); Tradjenta "is not recommended" in type 1 diabetes "as it would not be effective" (US 1). The UK linagliptin label says it "should not be used" in type 1 diabetes or to treat diabetic ketoacidosis (4.4).
- Glucose control with an eGFR below 45: dapagliflozin "not recommended" (Farxiga 1, 2.2).
- Pregnancy: Farxiga "is not recommended during the second and third trimesters of pregnancy" because of kidney effects in animal studies (US 8.1). The UK linagliptin label says "it is preferable to avoid the use of linagliptin during pregnancy" (4.6).
- Breastfeeding: "advise women that use of FARXIGA is not recommended while breastfeeding" (US 8.2).
- Children and adolescents: "treatment of children and adolescents with linagliptin is not recommended" (UK linagliptin 4.2).
- Past pancreatitis: not a contraindication, but Tradjenta "has not been studied" in people with a history of pancreatitis and the risk is unknown (US 1); the UK label says caution (4.4).
Prescription and legal status
- US: no FDA approved dapagliflozin and linagliptin combination; Farxiga, generic dapagliflozin and Tradjenta are prescription medicines. The FDA says personal importation of medicines is "illegal in most circumstances".
- UK: we found no combination on the UK emc database (which lists marketed products, not every MHRA licence); Forxiga and linagliptin 5 mg (formerly Trajenta) are prescription only medicines (POM).
- Australia: we found no combination on healthdirect (we did not search the ARTG directly); Forxiga and Trajenta are Schedule 4 (prescription only).
- Canada: no combination in the Health Canada Drug Product Database (searched 20 November 2026); Forxiga and Trajenta are prescription drugs. Glyxambi's Canadian listings are marked cancelled post market.
- India: sold on prescription (Apollo Pharmacy lists it as a "Prescription drug").
Buying genuine Oxra-L 10
Check that the carton says Oxra-L 10, dapagliflozin and linagliptin tablets, and Sun Pharma, and that the batch number and expiry on the strips match the carton. These checks help, but they cannot prove a tablet is genuine, and we have not confirmed the tablet's colour or markings. The MHRA warns: "Any medicine not authorised for sale in the UK can be unsafe or ineffective and there is no way of knowing what is in them or the negative health effects they can have." It advises UK buyers: "Only use UK-registered pharmacies, including online pharmacies displaying the official green cross logo". If a batch seems not to work, or causes symptoms, get medical advice and report it to the MHRA Yellow Card scheme, FDA MedWatch, the TGA or Health Canada, as well as to us.
Delivery
Orders reach the US, UK, Australia and Canada in 7 to 14 business days, in plain packaging with tracking. Shipping is $25 on orders under $149 and free from $149. Order well before your current supply runs out: stopping diabetes medicines suddenly can let your glucose rise.
Related guides
Sources
- FARXIGA (dapagliflozin) tablets, US prescribing information and Medication Guide, AstraZeneca. DailyMed setid 72ad22ae-efe6-4cd6-a302-98aaee423d69, version 49 (11 September 2026): sections 1, 2.1 to 2.5, 4, 5.1 to 5.4, 6.1 (Table 1), 7, 8.1, 8.2, 8.5, 8.7, 10, 12.1 to 12.3, 14.1 (Table 12).
- TRADJENTA (linagliptin) tablets, US prescribing information and Medication Guide, Boehringer Ingelheim. DailyMed setid c797ea5c-cab7-494b-9044-27eba0cfe40f, version 32 (effective 21 March 2025): sections 1, 2.1, 4, 5.1 to 5.6, 6.1 (Tables 1 and 2), 7, 8.4 to 8.7, 10, 12.2, 12.3, 14.2, 17.
- Linagliptin 5 mg film-coated tablets (previously known as Trajenta), UK SmPC, Boehringer Ingelheim, PLGB 14598/0225, revised January 2026 (emc 4762): sections 4.1 to 4.6.
- Forxiga 10 mg film-coated tablets, UK SmPC, AstraZeneca UK, PLGB 17901/0325, revised 10 July 2026 (emc 7607): section 4.4.
- CDSCO. Fixed dose combinations approved by DCG(I), January 2023 to December 2023 (item 19, 3 July 2023) and January 2024 to October 2024 (item 3, 11 January 2024).
- openFDA Drugs@FDA (dapagliflozin and linagliptin products), EMA medicines list, emc search, healthdirect and Health Canada Drug Product Database, searched 20 November 2026.
- NADAC (data.medicaid.gov), file as of 18 November 2026, rows effective 18 November 2026: generic dapagliflozin 10 mg (21 NDCs), Farxiga 10 mg, Tradjenta 5 mg, Glyxambi 10 mg/5 mg.
- CMS. Medicare Drug Price Negotiation Program: negotiated prices for initial price applicability year 2027 (Tradjenta).
- Jain A, et al. Fixed-dose combination dapagliflozin and linagliptin over linagliptin monotherapy in type 2 diabetes inadequately controlled with metformin. Diabetes Ther 2024. PMID 37957465.
- MHRA news release, 13 February 2026; FDA personal importation guidance.
- Indian listings: Tata 1mg, PharmEasy, Apollo Pharmacy, Truemeds (accessed 20 November 2026).
Frequently asked questions
What is Oxra-L 10?
Oxra-L 10 is a Sun Pharma tablet for adults with type 2 diabetes that contains two medicines: dapagliflozin 10 mg (an SGLT2 inhibitor) and linagliptin 5 mg (a DPP-4 inhibitor). India's regulator CDSCO approved this combination in July 2023 for people whose glucose is not controlled on metformin, so it is usually taken alongside metformin. It is sold in India in strips of 10 tablets.
Is Oxra-L the same as Farxiga and Tradjenta taken together?
It contains the same two active ingredients at the same doses as Farxiga 10 mg and Tradjenta 5 mg, but it is a different product. We found no dapagliflozin and linagliptin combination approved by the FDA, MHRA, TGA or Health Canada, and we have not seen data comparing Oxra-L with the two brand tablets. The licensed combinations of these drug classes are different pairs, such as Glyxambi (empagliflozin with linagliptin).
How much does Oxra-L 10 cost per tablet?
As of November 2026, $0.88 a tablet in the 60 pack ($53), $0.78 in the 120 pack ($94) and $0.68 in the 240 pack ($164), before shipping. Shipping is $25 under $149 and free from $149, so the 240 pack stays at $0.68 a tablet. The pack selector shows the current price. In the US, generic dapagliflozin alone costs pharmacies about 19 cents a tablet (NADAC, 18 November 2026), so if you only need dapagliflozin a US generic is cheaper.
How do I take Oxra-L 10?
One tablet once a day, with or without food, together with any metformin your doctor prescribes. If you miss a dose, take it when you remember, but never take two doses together. Your doctor should check your kidney function and fluid status first. Before surgery the Farxiga label says to withhold dapagliflozin for at least 3 days if possible; with this tablet that also stops the linagliptin, so ask how your glucose will be covered.
Which strength should I choose?
We sell only Oxra-L 10 (dapagliflozin 10 mg plus linagliptin 5 mg). Dapagliflozin 10 mg is the top US dose for glucose control, and the US label starts at 5 mg, so a doctor would usually move to Oxra-L 10 only once you are settled on dapagliflozin 10 mg. Linagliptin has a single labelled dose of 5 mg. If your doctor wants a different dapagliflozin dose, separate Forxiga 5mg or 10mg and Trajenta 5mg tablets allow that.
How long does a pack last?
At one tablet a day, the 60 pack lasts 60 days, the 120 pack 120 days and the 240 pack about eight months. Check that the expiry date on the strips runs past the date you will finish them, and agree the plan with your doctor before buying a large pack.
Can I take two tablets for better control?
No. Two tablets would give 20 mg of dapagliflozin and 10 mg of linagliptin, above both labelled doses. The Farxiga label treats 10 mg as the maximum and linagliptin is labelled at 5 mg once daily. If your glucose is not controlled, see your doctor; do not raise the dose yourself.
What are the side effects?
From the dapagliflozin label: genital fungal infections (6.9% of women on 10 mg against 1.5% on placebo; 2.7% of men against 0.3%), urinary tract infections and passing more urine. From the linagliptin label: nasopharyngitis, diarrhoea and cough at rates close to placebo. Serious but less common risks include ketoacidosis, Fournier's gangrene, dehydration and kidney injury (dapagliflozin), and pancreatitis, bullous pemphigoid, severe joint pain and allergic reactions (linagliptin).
Who should not take Oxra-L 10?
Never take it if you are allergic to linagliptin or any ingredient of the tablet, or have had a serious allergic reaction to dapagliflozin. It is not for type 1 diabetes, the dapagliflozin part is not recommended for glucose control when eGFR is below 45, Farxiga is not recommended in the second and third trimesters of pregnancy or while breastfeeding, and the UK linagliptin label says treatment of children and adolescents is not recommended. People with past pancreatitis, heart failure risk, or who take insulin or a sulfonylurea need their doctor's review first.
Do I need a prescription?
Yes. Oxra-L is sold on prescription in India, and its ingredients are prescription medicines in the US, UK, Australia and Canada, where this combination is not approved. The FDA says personal importation of medicines is illegal in most circumstances. Only take it under a doctor's care, with regular kidney and glucose checks.
How long does delivery take?
Orders reach the US, UK, Australia and Canada in 7 to 14 business days, in plain packaging with tracking. Shipping is $25 on orders under $149 and free from $149. Order before your current supply runs low so that you do not miss doses.
Medical References
- 1.FARXIGA (dapagliflozin) tablets, US prescribing information and Medication Guide, AstraZeneca (DailyMed SPL version 49) — 2026
- 2.TRADJENTA (linagliptin) tablets, US prescribing information and Medication Guide, Boehringer Ingelheim (DailyMed SPL version 32) — 2025
- 3.Linagliptin 5 mg film-coated tablets (previously known as Trajenta), UK Summary of Product Characteristics (Boehringer Ingelheim, PLGB 14598/0225, POM) — 2026
- 4.Forxiga 10 mg film-coated tablets, UK Summary of Product Characteristics (AstraZeneca UK, PLGB 17901/0325, POM) — 2026
- 5.CDSCO. Fixed dose combinations approved by DCG(I), January to December 2023 (linagliptin 5 mg + dapagliflozin 10 mg, 3 July 2023)
- 6.Jain A, et al. Fixed-dose combination dapagliflozin and linagliptin over linagliptin monotherapy in type 2 diabetes inadequately controlled with metformin. Diabetes Ther 2024;15:215-227 (PMID: 37957465) — 2023
- 7.CMS National Average Drug Acquisition Cost (NADAC) 2026: generic dapagliflozin 10 mg, Farxiga 10 mg, Tradjenta 5 mg and Glyxambi 10 mg/5 mg, effective 18 November 2026 — 2026
- 8.CMS Medicare Drug Price Negotiation Program: negotiated prices for initial price applicability year 2027 (Tradjenta)
- 9.Health Canada Drug Product Database: Trajenta DIN 02370921 and Forxiga (prescription); no dapagliflozin and linagliptin product (searched 20 November 2026)
- 10.healthdirect Australia: Trajenta (linagliptin 5 mg), Schedule 4
- 11.MHRA. 20 million illegal erectile dysfunction pills seized as MHRA warns against risky online buys — 2026
- 12.US Food and Drug Administration. Personal Importation
Sources: U.S. National Library of Medicine (DailyMed, PubMed), openFDA
Related articles
Customer Reviews
No reviews yet. Bought Oxra-L Tablet? Tell other buyers how it went.







